Including children and adolescents with schizophrenia in medication- free research

American Journal of Psychiatry

Volumn 156, Issue 7, 1999, Pages 1065-1068

  Kumra, Sanjiv ^a   Briguglio, Claudia ^a   Lenane, Marge ^a   Goldhar, Laura ^a   Bedwell, Jeffrey ^a   Venuchekov, Julia ^a   Jacobsen, Leslie K ^a   Rapoport, Judith L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; HOSPITALIZATION; HUMAN; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

ADOLESCENTS; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL APPROACH/SOURCE; EMPIRICAL APPROACH; MENTAL HEALTH THERAPIES; MENTALLY ILL; NATIONAL INSTITUTE OF MENTAL HEALTH; RISKS AND BENEFITS;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL PROTOCOLS; DIAGNOSTIC ERRORS; ETHICS, MEDICAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MENTALLY ILL PERSONS; PERSONALITY DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RESEARCH DESIGN; RISK ASSESSMENT; SCHIZOPHRENIA, CHILDHOOD; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 0032970103     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Carpenter WT Jr, Schooler NR, Kane JM: The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997; 54:401-407
2. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54:49-55
3. Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:235-280
4. Fins JJ, Miller FG: The call of the sirens: navigating the ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1998; 54:415-416
5. Meltzer H: Neuroleptic withdrawal in schizophrenic patients: an idea whose time has come. Arch Gen Psychiatry 1995; 52: 200-202
6. Arnold LE, Stoff DE, Cook E, Cohen DJ, Kruesi M, Wright C, Hattab J, Graham P, Zametkin A, Castellanos FX, McMahon W, Leckman JF: Ethical issues in biological psychiatric research with children and adolescents. J Am Acad Child Adolesc Psychiatry 1995; 34:929-939
7. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J: Childhood and adolescent depression: a review of the past 10 years, part II. J Am Acad Child Adolesc Psychiatry 1996; 35: 1575-1583
8. Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK: Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychiatry 1979; 14:601-613
9. Rapoport JL, Mikkelsen JE, Zavadil A, Nee L, Gruenau C, Mendelson W, Gillin JC: Childhood enuresis, II: psychopathology, tricyclic concentration in plasma, and antienuretic effect. Arch Gen Psychiatry 1980; 37:1146-1152
10. Rapoport JL, Potter WZ: Tricyclic Antidepressants: Use in Pediatric Psychopharmacology, in Pharmacokinetics, Youth and Age. Amsterdam, Elsevier, 1981, pp 105-123
11. Potter WZ, Calil H, Sutfin T, Zavadil A, Rapoport JL, Goodwin F: Active metabolites of imipramine and desipramine in man. Clin Neuropharmacol 1982; 31:393-401
12. Klin A, Cohen DJ: The immorality of not knowing: the ethical imperative to conduct research in child and adolescent psychiatry, in Ethics in Child Psychiatry. Edited by Hattab J. Jerusalem, Gelfen Publishing House, 1994, pp 15-30
13. Berglund CA: Children in Medical Research: Australian Ethical Standards, vol 21. New South Wales, Australia, University of Wollongong, Department of Science and Technology Studies, 1995, pp 149-159
14. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090-1097
15. Kumra S, Jacobsen LK, Lenane M, Karp BI, Frazier JA, Smith A, Bedwell J, Lee P, Malanga CJ, Hamburger SD, Rapoport JL: Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37:377-385
16. Kumra S, Jacobsen LK, Lenane M, Zahn TP, Wiggs E, Alaghband-Rad J, Castellanos FX, Frazier JA, McKenna K, Gordon CT, Smith A, Hamburger S, Rapoport JL: "Multidimensionally impaired disorder": is it a variant of very early-onset schizophrenia? J Am Acad Child Adolesc Psychiatry 1998; 37:91-99
17. McKenna K, Gordon CT, Lenane M, Kaysen D, Fahey K, Rapoport JL: Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 1994; 33:636-644
18. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1984
19. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
20. Campbell M, Palig M: Subjective Treatment Emergent Symptoms Scale (STESS). Psychopharmacol Bull 1985; 21:1063-1082
21. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 1983; 40:1228-1231
22. Puig-Antich J, Orvaschel H, Tabrizi M, Chambers W: The Schedule for Affective Disorders and Schizophrenia for School-Age Children - Epidemiologic Version (Kiddie-SADS-E), 3rd ed. New York, New York State Psychiatric Institute and Yale University School of Medicine, 1980
23. Asarnow JR, Tompson MC, Goldstein MJ: Childhood-onset schizophrenia: a follow-up study. Schizophr Bull 1994; 20: 599-617
24. Carpenter WT Jr, Schooler NR, Kane JM: Medication removal and research in psychotic disorders. Arch Gen Psychiatry 1998; 55:282-283
25. Kane J, Schooler NR, Marder S, Simpson G, Casey DE: Methods for clinical evaluation of pharmacologic treatments of schizophrenia, in Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. Edited by Prien RF, Robinson DS. New York, Raven Press, 1994, pp 171-189
26. Volavka J: Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs? Arch Gen Psychiatry 1998; 55:280-281
27. Gilbert PL, Harris J, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52:173-188
28. Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW: Continued versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147:1138-1148
29. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J: Intermittent vs maintenance medication in schizophrenia. Arch Gen Psychiatry 1991; 48: 333-339